Preliminary findings demonstrate an improvement in eGFR slope in nearly all patients with SCD after treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
September is National Sickle Cell Awareness Month. The blood disorder occurs among about one of every 365 Black births and one of every 16,300 Latino births, according to the CDC.